Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites

Clinical Infectious Diseases

Volumn 68, Issue 7, 2019, Pages 1223-1224

  Miller, Loren G ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAROLINE; CIPROFLOXACIN; DALBAVANCIN; DAPTOMYCIN; DELAFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; ORITAVANCIN; TEDIZOLID; TELAVANCIN; TEMAFLOXACIN; TROVAFLOXACIN; VANCOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTIOUS DISEASE SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; DOUBLE BLIND PROCEDURE; SPECIALIZATION;

ANTI-BACTERIAL AGENTS; AZTREONAM; DOUBLE-BLIND METHOD; FLUOROQUINOLONES; HUMANS; INFECTIONS; SPECIALIZATION; VANCOMYCIN;

EID: 85063723382     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy720     Document Type: Note

References (18)

1. Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC Infect Dis 2015; 15:362.
2. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10-52.
3. Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect 2016; 22(suppl 2):S27-36.
4. O'Riordan WO, McManus A, Teras J, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: A phase 3, multinational, double-blind, randomized study. Clin Infect Dis 2018.
5. Pfaller MA, Sader HS, Rhomberg PR, Flamm RK. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother 2017; 61:e02609-16.
6. McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2017; 61:e00772-17.
7. Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: A novel anionic fluoroquinolone. J Antimicrob Chemother 2018; 73:1439-51.
8. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther 2005; 27:1329-42.
9. Mandell L, Tillotson G. Safety of fluoroquinolones: An update. Can J Infect Dis 2002; 13:54-61.
10. Food and Drug Administration. Determination that TEQUIN (Gatifloxacin) was withdrawn from sale for reasons of safety. Fed Regit 2008; 73:52357-8.
11. Gade ND, Qazi MS. Fluoroquinolone therapy in Staphylococcus aureus infections: Where do we stand? J Lab Physicians 2013; 5:109-12.
12. Fralick M, Macdonald EM, Gomes T, et al; Canadian Drug Safety and Effectiveness Research Network. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: Population based study. BMJ 2014; 349:g6196.
13. Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015; 187:E138-43.
14. Uhlemann AC, Hafer C, Miko BA, et al. Emergence of sequence type 398 as a community- And healthcare-associated methicillin-susceptible Staphylococcus aureus in northern Manhattan. Clin Infect Dis 2013; 57:700-3.
15. Bamgbola O. Review of vancomycin-induced renal toxicity: An update. Ther Adv Endocrinol Metab 2016; 7:136-47.
16. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11.
17. Brachman PS. Infectious diseases-past, present, and future. Int J Epidemiol 2003; 32:684-6.
18. Levine DP. Vancomycin: A history. Clin Infect Dis 2006; 42(suppl 1):S5-12.